Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service in England, Wales and Scotland to treat severe thrombocytopenia in adults with chronic liver disease who are undergoing invasive procedures.
Shionogi today announce that the National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) have published positive appraisals recommending the use of Mulpleo (lusutrombopag) by the NHS in England, Wales and Scotland for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing planned invasive procedures.
These two recommendations are based principally on evidence from L-PLUS 18 and L-PLUS 29, two multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase III studies where 312 patients with CLD, severe thrombocytopenia with a platelet count of <50,000/µL and a scheduled invasive procedure received either lusutrombopag or placebo once daily for up to seven days.
